Annual SGA
$10.83 M
+$1.35 M+14.26%
December 31, 2023
Summary
- As of February 7, 2025, SBFM annual SGA is $10.83 million, with the most recent change of +$1.35 million (+14.26%) on December 31, 2023.
- During the last 3 years, SBFM annual SGA has risen by +$10.22 million (+1685.33%).
- SBFM annual SGA is now at all-time high.
Performance
SBFM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$3.73 M
+$733.40 K+24.52%
September 30, 2024
Summary
- As of February 7, 2025, SBFM quarterly SGA is $3.73 million, with the most recent change of +$733.40 thousand (+24.52%) on September 30, 2024.
- Over the past year, SBFM quarterly SGA has increased by +$1.28 million (+52.55%).
- SBFM quarterly SGA is now -41.91% below its all-time high of $6.41 million, reached on December 31, 2022.
Performance
SBFM Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$261.66 M
-$4.23 M-1.64%
September 30, 2024
Summary
- As of February 7, 2025, SBFM TTM SGA is -$261.66 million, with the most recent change of -$4.23 million (-1.64%) on September 30, 2024.
- Over the past year, SBFM TTM SGA has dropped by -$276.11 million (-1911.28%).
- SBFM TTM SGA is now -1194697.26% below its all-time high of -$21.90 thousand.
Performance
SBFM TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
SBFM Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.3% | +52.5% | -1911.3% |
| 3 y3 years | +1685.3% | +51.0% | -2048.9% |
| 5 y5 years | +852.4% | +51.0% | -2048.9% |
SBFM Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +480.4% | -41.9% | +1681.4% | -115.1% | at low |
| 5 y | 5-year | at high | +1685.3% | -41.9% | +8897.6% | -289.7% | at low |
| alltime | all time | at high | >+9999.0% | -41.9% | >+9999.0% | <-9999.0% | at low |
Sunshine Biopharma Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $3.73 M(+24.5%) | $12.90 M(+11.0%) |
| Jun 2024 | - | $2.99 M(-11.1%) | $11.62 M(+4.7%) |
| Mar 2024 | - | $3.36 M(+19.3%) | $11.09 M(+2.2%) |
| Dec 2023 | $10.83 M(+14.3%) | $2.82 M(+15.5%) | $10.85 M(-24.9%) |
| Sep 2023 | - | $2.44 M(-1.0%) | $14.45 M(+7.6%) |
| Jun 2023 | - | $2.47 M(-21.1%) | $13.43 M(+14.9%) |
| Mar 2023 | - | $3.13 M(-51.3%) | $11.68 M(+23.3%) |
| Dec 2022 | $9.48 M(+408.0%) | $6.41 M(+351.0%) | $9.48 M(+189.4%) |
| Sep 2022 | - | $1.42 M(+96.6%) | $3.28 M(+52.0%) |
| Jun 2022 | - | $723.20 K(-21.5%) | $2.16 M(+29.8%) |
| Mar 2022 | - | $921.40 K(+340.7%) | $1.66 M(-11.0%) |
| Dec 2021 | $1.87 M(+207.6%) | - | - |
| Dec 2021 | - | $209.10 K(-30.6%) | $1.87 M(-7.3%) |
| Sep 2021 | - | $301.50 K(+32.2%) | $2.01 M(+12.7%) |
| Jun 2021 | - | $228.00 K(-79.8%) | $1.79 M(+5.5%) |
| Mar 2021 | - | $1.13 M(+217.0%) | $1.69 M(+179.0%) |
| Dec 2020 | $606.60 K(-2.6%) | $355.60 K(+376.7%) | $606.70 K(+20.2%) |
| Sep 2020 | - | $74.60 K(-44.8%) | $504.60 K(-18.1%) |
| Jun 2020 | - | $135.10 K(+226.3%) | $616.00 K(+13.0%) |
| Mar 2020 | - | $41.40 K(-83.7%) | $545.30 K(-12.4%) |
| Dec 2019 | $622.70 K(-45.2%) | $253.50 K(+36.3%) | $622.80 K(+25.5%) |
| Sep 2019 | - | $186.00 K(+188.8%) | $496.20 K(-16.7%) |
| Jun 2019 | - | $64.40 K(-45.8%) | $595.80 K(-46.2%) |
| Mar 2019 | - | $118.90 K(-6.3%) | $1.11 M(-3.3%) |
| Dec 2018 | $1.14 M(+33.7%) | $126.90 K(-55.6%) | $1.15 M(-2.8%) |
| Sep 2018 | - | $285.60 K(-50.5%) | $1.18 M(+17.5%) |
| Jun 2018 | - | $576.80 K(+268.8%) | $1.00 M(+11.7%) |
| Mar 2018 | - | $156.40 K(-2.5%) | $898.50 K(+5.6%) |
| Dec 2017 | $850.60 K(-5.4%) | $160.40 K(+45.8%) | $850.60 K(-15.8%) |
| Sep 2017 | - | $110.00 K(-76.7%) | $1.01 M(+0.9%) |
| Jun 2017 | - | $471.70 K(+334.7%) | $1.00 M(+5.0%) |
| Mar 2017 | - | $108.50 K(-66.1%) | $953.70 K(+6.0%) |
| Dec 2016 | $899.60 K | $320.50 K(+217.0%) | $899.60 K(+20.1%) |
| Sep 2016 | - | $101.10 K(-76.1%) | $749.10 K(-0.4%) |
| Jun 2016 | - | $423.60 K(+678.7%) | $752.40 K(+7.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | $54.40 K(-68.0%) | $698.70 K(-9.2%) |
| Dec 2015 | $769.10 K(-46.1%) | $170.00 K(+62.8%) | $769.10 K(-14.7%) |
| Sep 2015 | - | $104.40 K(-71.8%) | $901.40 K(-16.1%) |
| Jun 2015 | - | $369.90 K(+196.4%) | $1.07 M(-6.3%) |
| Mar 2015 | - | $124.80 K(-58.7%) | $1.15 M(-13.9%) |
| Dec 2014 | $1.43 M(-20.6%) | $302.30 K(+9.0%) | $1.33 M(-16.8%) |
| Sep 2014 | - | $277.40 K(-37.3%) | $1.60 M(+6.6%) |
| Jun 2014 | - | $442.50 K(+42.8%) | $1.50 M(+23.9%) |
| Mar 2014 | - | $309.90 K(-45.8%) | $1.21 M(-32.7%) |
| Dec 2013 | $1.80 M(+155.2%) | $571.40 K(+221.6%) | $1.80 M(+27.0%) |
| Sep 2013 | - | $177.70 K(+16.4%) | $1.42 M(-12.3%) |
| Jun 2013 | - | $152.60 K(-83.0%) | $1.62 M(+3.3%) |
| Mar 2013 | - | $899.50 K(+377.7%) | $1.57 M(+122.0%) |
| Dec 2012 | $704.90 K(+70.4%) | $188.30 K(-50.0%) | $704.90 K(-7.7%) |
| Sep 2012 | - | $376.40 K(+273.0%) | $763.70 K(+51.6%) |
| Jun 2012 | - | $100.90 K(+156.7%) | $503.70 K(+20.1%) |
| Mar 2012 | - | $39.30 K(-84.1%) | $419.30 K(+1.9%) |
| Dec 2011 | $413.60 K(-23.0%) | $247.10 K(+112.3%) | $411.60 K(-30.4%) |
| Sep 2011 | - | $116.40 K(+605.5%) | $591.40 K(-6.9%) |
| Jun 2011 | - | $16.50 K(-47.8%) | $635.40 K(-71.2%) |
| Mar 2011 | - | $31.60 K(-92.6%) | $2.21 M(-0.1%) |
| Dec 2010 | $537.40 K(+437.4%) | $426.90 K(+166.1%) | $2.21 M(+23.9%) |
| Sep 2010 | - | $160.40 K(-89.9%) | $1.78 M(+7.8%) |
| Jun 2010 | - | $1.59 M(+4489.9%) | $1.65 M(+2204.6%) |
| Mar 2010 | - | $34.60 K(+8.1%) | $71.80 K(+66.6%) |
| Dec 2009 | $100.00 K(+536.9%) | - | - |
| Oct 2009 | - | $32.00 K(+515.4%) | $43.10 K(+174.5%) |
| Jul 2009 | $15.70 K(-39.8%) | $5200.00(+108.0%) | $15.70 K(+6.8%) |
| Apr 2009 | - | $2500.00(-26.5%) | $14.70 K(-36.1%) |
| Jan 2009 | - | $3400.00(-26.1%) | $23.00 K(+5.0%) |
| Oct 2008 | - | $4600.00(+9.5%) | $21.90 K(-16.1%) |
| Jul 2008 | $26.10 K(+99.2%) | $4200.00(-61.1%) | $26.10 K(+19.2%) |
| Apr 2008 | - | $10.80 K(+369.6%) | $21.90 K(+97.3%) |
| Jan 2008 | - | $2300.00(-73.9%) | $11.10 K(+26.1%) |
| Oct 2007 | - | $8800.00 | $8800.00 |
| Jul 2007 | $13.10 K | - | - |
FAQ
- What is Sunshine Biopharma annual SGA?
- What is the all time high annual SGA for Sunshine Biopharma?
- What is Sunshine Biopharma annual SGA year-on-year change?
- What is Sunshine Biopharma quarterly SGA?
- What is the all time high quarterly SGA for Sunshine Biopharma?
- What is Sunshine Biopharma quarterly SGA year-on-year change?
- What is Sunshine Biopharma TTM SGA?
- What is the all time high TTM SGA for Sunshine Biopharma?
- What is Sunshine Biopharma TTM SGA year-on-year change?
What is Sunshine Biopharma annual SGA?
The current annual SGA of SBFM is $10.83 M
What is the all time high annual SGA for Sunshine Biopharma?
Sunshine Biopharma all-time high annual SGA is $10.83 M
What is Sunshine Biopharma annual SGA year-on-year change?
Over the past year, SBFM annual SGA has changed by +$1.35 M (+14.26%)
What is Sunshine Biopharma quarterly SGA?
The current quarterly SGA of SBFM is $3.73 M
What is the all time high quarterly SGA for Sunshine Biopharma?
Sunshine Biopharma all-time high quarterly SGA is $6.41 M
What is Sunshine Biopharma quarterly SGA year-on-year change?
Over the past year, SBFM quarterly SGA has changed by +$1.28 M (+52.55%)
What is Sunshine Biopharma TTM SGA?
The current TTM SGA of SBFM is -$261.66 M
What is the all time high TTM SGA for Sunshine Biopharma?
Sunshine Biopharma all-time high TTM SGA is -$21.90 K
What is Sunshine Biopharma TTM SGA year-on-year change?
Over the past year, SBFM TTM SGA has changed by -$276.11 M (-1911.28%)